THE ACCREDITATION COUNCIL FOR MEDICAL AFFAIRS (ACMA) DEVELOPS FIRST EVER BOARD-CERTIFIED BIOLOGICS & BIOSIMILARS SPECIALIST (BCBBS) CERTIFICATION
THE ACCREDITATION COUNCIL FOR MEDICAL AFFAIRS (ACMA) DEVELOPS FIRST EVER BOARD-CERTIFIED BIOLOGICS & BIOSIMILARS SPECIALIST (BCBBS) CERTIFICATION
NEW YORK, Dec. 6, 2022 /PRNewswire/ -- The Accreditation Council for Medical Affairs (ACMA) is launching a new Board Certification program focused on biologics and biosimilars. This is the first and only accredited board certification in the biologics and biosimilars arena.
紐約，2022年12月6日/美通社/--醫療事務認證委員會(ACMA)正在推出一項新的委員會認證計劃，重點是生物製劑和生物仿製藥。這是生物製品和生物仿製藥領域第一個也是唯一一個經過認可的委員會認證。
The Board-Certified Biologics and Biosimilars Specialist (BCBBS) program will accredit, and board certify healthcare professionals such as pharmacists (PharmDs), MDs, PhDs, and Medical Affairs/MSL professionals. With recent guidelines from Food and Drug Administration (FDA) and Heads of Medicines' Agencies (HMA) Biosimilar Working Group in Europe addressing biosimilars interchangeability, the need for education among the medical and scientific community is vital.
董事會認證的生物製品和生物仿製藥專家(BCBBS)計劃將授權和董事會認證醫療保健專業人員，如藥劑師(Pharmd)、醫學博士、博士和醫療事務/MSL專業人員。隨着食品和藥物管理局(FDA)和歐洲藥品機構負責人(HMA)生物相似工作組最近提出的關於生物仿製藥可互換性的指導方針，醫學界和科學界對教育的需求至關重要。
ACCREDITATION COUNCIL FOR MEDICAL AFFAIRS (ACMA) DEVELOPS FIRST BOARD-CERTIFIED BIOLOGICS & BIOSIMILARS CERTIFICATION
醫療事務認證委員會(ACMA)開發了第一個委員會認證的生物製品和生物仿製藥認證
William Soliman, Ph.D., BCMAS, ACMA Founder and CEO, said, "The role that biologics and biosimilars play in the treatment of various chronic diseases is growing rapidly. Helping both the healthcare and life sciences industry better understand appropriate clinical use of biologics and biosimilars will be key to successful long-term patient outcomes."
ACMA創始人兼首席執行官威廉·索裏曼博士説：“生物製劑和生物仿製藥在治療各種慢性病中發揮的作用正在迅速增長。幫助醫療保健和生命科學行業更好地瞭解生物製劑和生物仿製藥的適當臨牀使用將是患者取得成功的長期結果的關鍵。”
Currently, biologics and biosimilars board certification does not exist in the industry. The BCBBS certification will cover important topics such as regulatory and scientific concepts for biologics, real-world evidence, economic considerations, FDA resources including the Purple Book Database, and the future outlook on biosimilars. The program is self-paced and online to enable learners from around the world to enroll.
目前，生物製品和生物仿製藥委員會認證在行業中還不存在。BCBBS認證將涵蓋重要的主題，如生物製品的監管和科學概念、現實世界的證據、經濟考慮、FDA的資源，包括紫皮書數據庫，以及生物仿製藥的未來展望。該計劃是自定進度和在線的，使來自世界各地的學習者能夠註冊。
As analysts predict, the global biologics and biosimilars market will continue to grow to be a critical part of the healthcare industry. The expansion of biologic treatment options through market entrance of biosimilars across several therapeutic areas offer multiple advantages that will ultimately benefit patients and the overall healthcare delivery system. Understanding biologics and biosimilars in the medical and scientific community will help not only accelerate potential development of new treatments through advanced biotechnology capabilities.
正如分析師預測的那樣，全球生物製品和生物仿製藥市場將繼續增長，成為醫療保健行業的關鍵部分。通過生物仿製藥在幾個治療領域的市場準入擴大生物治療選擇提供了多種優勢，最終將使患者和整個醫療保健提供系統受益。瞭解醫學和科學界的生物製劑和生物仿製藥不僅有助於通過先進的生物技術能力加速新療法的潛在開發。
About the Accreditation Council for Medical Affairs (ACMA) The ACMA is a global organization providing award-winning solutions for certification, training, analytics, and insights to support the healthcare and life sciences industries. From Medical Affairs to Market Access, Managed Care, and Market Research, ACMA is the standard in the industry for certifying and credentialing prior authorization and medical affairs professionals in over 80+ countries. To learn more, visit medicalaffairsspecialist.org.
關於醫療事務認證委員會(ACMA)ACMA是一家全球組織，提供屢獲殊榮的認證、培訓、分析和見解解決方案，以支持醫療保健和生命科學行業。從醫療事務到市場準入、管理醫療和市場研究，ACMA是80多個國家和地區認證和認證預先授權和醫療事務專業人員的行業標準。要了解更多信息，請訪問Medicalaffairsspecialist.org.
SOURCE Accreditation Council for Medical Affairs (ACMA)
醫療事務來源認證委員會(ACMA)
譯文內容由第三人軟體翻譯。